|
Dihydrofolate Reductase Inhibitors [MoA] |
|
Cytochrome P450 2C19 Inhibitors [MoA] |
|
GABA A Agonists [MoA] |
|
Cytochrome P450 3A4 Inhibitors [MoA] |
|
Adrenergic alpha-Agonists [MoA] |
|
Cytochrome P450 2C9 Inhibitors [MoA] |
|
Cytochrome P450 2C19 Inducers [MoA] |
|
Cytochrome P450 2B6 Inducers [MoA] |
|
Cytochrome P450 3A Inhibitors [MoA] |
|
Cytochrome P450 1A2 Inducers [MoA] |
|
Cytochrome P450 2C9 Inducers [MoA] |
|
Adrenergic alpha-Antagonists [MoA] |
|
Adrenergic beta1-Antagonists [MoA] |
|
Cytochrome P450 2C8 Inhibitors [MoA] |
|
Cytochrome P450 2D6 Inhibitors [MoA] |
|
Cytochrome P450 1A2 Inhibitors [MoA] |
|
mTOR Inhibitors [MoA] |
|
Cytochrome P450 3A4 Inducers [MoA] |
|
Acidifying Activity [MoA] |
|
Breast Cancer Resistance Protein Inhibitors [MoA] |
|
Organic Cation Transporter 2 Inhibitors [MoA] |
|
Cytochrome P450 3A5 Inhibitors [MoA] |
|
Serotonin 1b Receptor Agonists [MoA] |
|
Cytochrome P450 3A Inducers [MoA] |
|
Carbonic Anhydrase Inhibitors [MoA] |
|
Calcineurin Inhibitors [MoA] |
|
Calcium Chelating Activity [MoA] |
|
Interleukin-12 Antagonists [MoA] |
|
Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA] |
|
Cytochrome P450 2C8 Inducers [MoA] |
|
Organic Anion Transporter 1 Inhibitors [MoA] |
|
Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA] |
|
G-Protein-linked Receptor Interactions [MoA] |
|
Catechol O-Methyltransferase Inhibitors [MoA] |
|
Hydroxyphenylpyruvate Dioxygenase Inhibitors [MoA] |
|
HIV Protease Inhibitors [MoA] |
|
Cytochrome P450 2E1 Inducers [MoA] |
|
P-Glycoprotein Inhibitors [MoA] |
|
Estrogen Receptor Antagonists [MoA] |
|
Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA] |
|
UGT1A9 Inhibitors [MoA] |
|
AMPA Receptor Antagonists [MoA] |
|
Sigma-1 Receptor Agonists [MoA] |
|
Adrenergic beta3-Agonists [MoA] |
|
Non-Nucleoside Reverse Transcriptase Inhibitors [MoA] |
|
Cyclooxygenase Inhibitors [MoA] |
|
Calcium Channel Antagonists [MoA] |
|
Cytochrome P450 2D6 Inducers [MoA] |
|
Androgen Receptor Agonists [MoA] |
|
Chloride Channel Activation Potentiators [MoA] |
|
Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA] |
|
Cholinergic Antagonists [MoA] |
|
Angiotensin 2 Receptor Antagonists [MoA] |
|
Bcr-Abl Tyrosine Kinase Inhibitors [MoA] |
|
Janus Kinase Inhibitors [MoA] |
|
Enzyme Stabilizers [MoA] |
|
Mitogen-Activated Protein Kinase Kinase 1 Inhibitors [MoA] |
|
Cytochrome P450 2B6 Inhibitors [MoA] |
|
Pyruvate Kinase Activators [MoA] |
|
Adrenergic beta-Agonists [MoA] |
|
Dipeptidyl Peptidase 4 Inhibitors [MoA] |
|
Organic Anion Transporting Polypeptide 2B1 Inhibitors [MoA] |
|
Bile Salt Export Pump Inhibitors [MoA] |
|
DNA Terminase Complex Inhibitors [MoA] |
|
Organic Cation Transporter 1 Inhibitors [MoA] |
|
Kinase Inhibitors [MoA] |